What is Core Laboratories N.V.'s stock symbol?
Core Laboratories N.V. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."
How often does Core Laboratories N.V. pay dividends? What is the dividend yield for Core Laboratories N.V.?
Core Laboratories N.V. announced a quarterly dividend on Tuesday, January 10th. Investors of record on Friday, January 20th will be given a dividend of $0.55 per share on Friday, February 17th. This represents a $2.20 dividend on an annualized basis and a yield of 1.93%. The ex-dividend date of this dividend is Wednesday, January 18th.
Where is Core Laboratories N.V.'s stock going? Where will Core Laboratories N.V.'s stock price be in 2017?
13 brokers have issued 12-month target prices for Core Laboratories N.V.'s shares. Their predictions range from $91.00 to $180.00. On average, they expect Core Laboratories N.V.'s stock price to reach $123.83 in the next twelve months.
When will Core Laboratories N.V. announce their earnings?
Core Laboratories N.V. is scheduled to release their next quarterly earnings announcement on Tuesday, April, 18th 2017.
What are analysts saying about Core Laboratories N.V. stock?
Here are some recent quotes from research analysts about Core Laboratories N.V. stock:
According to Zacks Investment Research, "Core Laboratories' was able to meet the fourth-quarter 2016 earnings on the back of increased U.S. onshore oil production.We like Core Labs’ leadership position in the reservoir optimization niche, along with its global footprint and deep portfolio of proprietary products and services. Furthermore, CLB’s low asset intensive operations and limited capex needs allow it to generate substantial free cash flows. However,Core Labs’ revenues are largely dependent on the completion and stimulation of wells. As seen for the fourth quarter, well completions increased only 2% on a sequential quarterly basis. Hence, lesser number of new wells and delayed production can pose a threat to Core Labs earnings and revenues." (1/30/2017)
J P Morgan Chase & Co analysts commented, "have run too hard too fast" with 39 percent downside to December '16 target price."[W]e think expectations have run too hard with other NAM beta plays, and a re-rating could lead to underperformance in 2H16 relative to equipment peers," analyst Sean Meakim wrote in a note.On the industry front, the analyst said flagging oil prices could easily crush hopes that E&P inquiries in NAM translate to material incremental work in the second half (or even 2017).Even if activity levels improve in the second half, Meakim remains concerned that production declines may soften, resulting in a less constructive oil price environment yield than what is necessary to instigate the next upcycle.Related Link: Exxon And Chevron's New $37-Billion Project Is "Inflection Point" For Oil Market"We think investor focus this earnings season is on confirming a 2Q bottom, but with expectations already implying 2H improvement, we believe disappointment could bring a broader pullback in the stocks," Meakim highlighted.Meanwhile, Forum Energy shares have risen significantly since February on better expectations for normalized activity next cycle. That said, the company is still cautious on the outlook for second half.Further, the analyst sees the possibility for a retreat as expectations reset in the second half if oil prices struggle to move higher and rig counts remain volatile. "Admittedly some of the heat has come off the stock already (-14 percent off its June 7 high v. -8 percent OSX), but we see more room to run," (7/12/2016)
Who owns Core Laboratories N.V. stock?
Core Laboratories N.V.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (1.87%), Franklin Resources Inc. (1.42%), State Street Corp (1.20%), Van ECK Associates Corp (1.05%), Champlain Investment Partners LLC (0.98%) and Congress Asset Management Co. MA (0.96%). Company insiders that own Core Laboratories N.V. stock include Jan Willem Sodderland, Martha Z Carnes, Michael C Kearney and Michael Straughen.
Who sold Core Laboratories N.V. stock? Who is selling Core Laboratories N.V. stock?
Core Laboratories N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Marshall Wace LLP, Fiera Capital Corp, Friedberg Investment Management, Janus Capital Management LLC, AQR Capital Management LLC, Columbia Wanger Asset Management LLC and Capital Guardian Trust Co..
Who bought Core Laboratories N.V. stock? Who is buying Core Laboratories N.V. stock?
Core Laboratories N.V.'s stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Congress Asset Management Co. MA, AKO Capital LLP, Baird Financial Group Inc., Asset Management One Co. Ltd., Van ECK Associates Corp, Franklin Resources Inc. and Precocity Capital LP. Company insiders that have bought Core Laboratories N.V. stock in the last two years include Jan Willem Sodderland, Martha Z Carnes and Michael Straughen.
How do I buy Core Laboratories N.V. stock?
Shares of Core Laboratories N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Core Laboratories N.V. stock cost?
One share of Core Laboratories N.V. stock can currently be purchased for approximately $114.12.